Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
Second Genome received early financing of $5.0M on 2011-08-09.
| Series | Round size | Date |
|---|---|---|
| Series A | $5.0M | 08/2011 |
| Series A | $6.5M | 06/2013 |
| Series B | $51M | 04/2016 |
| Investors | Security type |
|---|---|
| ADVANCED TECHNOLOGY VENTURES | Series A |
| Morgenthaler Ventures | Series A |
| Wavepoint Ventures | Series A |
| SR One | Series B |
| MBL Venture Capital Co Ltd | Series B |
| Pfizer Venture Investments | Series B |
| Adveq | Series B |
| Roche Venture Fund | Series B |
| Mayo Clinic | Series B |
| ADVANCED TECHNOLOGY VENTURES | Series B |
| Morgenthaler Ventures | Series B |
| Lifeforce Capital | Series B |
| Digitalis Ventures | Series B |
| Matt Winkler | Series B |
| Seraph Group | Series B |
Second Genome's top competitor, Vertex Pharmaceuticals, earned an annual revenue of $11.0B.
Second Genome's smallest competitor is Phosphorus with revenue of $1.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Seagen | $85,008 | $2.0B | 900 | - |
| Sarepta Therapeutics | $94,985 | $1.9B | 840 | 16 |
| Acadia Pharmaceuticals | $90,533 | $957.8M | 570 | 100 |
| Exelixis | $108,978 | $2.2B | 484 | 161 |
| Geron | $56,851 | $77.0M | 15 | - |
| BioReliance | $74,348 | $49.9M | 700 | - |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 140 |
| Cepheid | $86,295 | $531.1M | 6,000 | 6 |
| Zoetis | $87,092 | $9.3B | 11,300 | 178 |
| Ligand Pharmaceuticals | $82,001 | $241.5M | 116 | - |
Zippia gives an in-depth look into the details of Second Genome, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Second Genome. The employee data is based on information from people who have self-reported their past or current employments at Second Genome. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Second Genome. The data presented on this page does not represent the view of Second Genome and its employees or that of Zippia.
Second Genome may also be known as or be related to Second Genome, Second Genome Inc, Second Genome Inc. and Second Genome, Inc.